Literature DB >> 17301691

Interactions with other human UDP-glucuronosyltransferases attenuate the consequences of the Y485D mutation on the activity and substrate affinity of UGT1A6.

Mika Kurkela1, Anne-Sisko Patana, Peter I Mackenzie, Michael H Court, Christopher G Tate, Jouni Hirvonen, Adrian Goldman, Moshe Finel.   

Abstract

OBJECTIVES: To explore the possible role of hetero-oligomerization among the human UDP-glucuronosyltransferases in attenuating the consequences of the pathological Y486D mutation (UGT1A1 numbering) that often causes hyperbilirubinaemia. Owing to exon sharing in the human UGT1A gene, the equivalent mutation is present in all other UGT1As of the affected individuals. It is unknown, however, if this mutation results in clinical conditions, other than impaired bilirubin conjugation by UGT1A1.
METHODS: The main experimental approach in this study was to try and form hetero-oligomers of selected UDP-glucuronosyltransferases by coinfecting insect cells with recombinant baculoviruses that encode different human UDP-glucuronosyltransferases and mutants thereof. The infected cells were analysed for both relative expression levels and catalytic activity in each case, the combination of which yielded normalized activity. Kinetic analyses and copurification by affinity chromatography were also performed.
RESULTS: Coinfections with UGT1A4 increased the normalized scopoletin glucuronidation of 6YD (the Y485D mutant of UGT1A6) much more than it affected 1YD (the Y486D mutant of UGT1A1). Serotonin glucuronidation analyses revealed that coexpression of 6YD with most other human UDP-glucuronosyltransferases significantly increased the normalized activity of this mutant. Using 1-naphthol as the aglycone substrate, the Km of 6YD for the cosubstrate UDP-glucuronic acid was about 50 times higher than in UGT1A6. Yet, coexpression of 6YD with UGT1A4 lowered the Km for UDP-glucuronic acid to the level of UGT1A6. Coexpression also influenced wild-type UGT1A6 and UGT2B7, increasing the normalized activity of UGT1A6, but decreasing it for UGT2B7.
CONCLUSION: Hetero-oligomerization may play an important role in UDP-glucuronosyltransferases activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17301691     DOI: 10.1097/FPC.0b013e328011b598

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  14 in total

1.  Modulation of the human glucuronosyltransferase UGT1A pathway by splice isoform polypeptides is mediated through protein-protein interactions.

Authors:  Judith Bellemare; Mélanie Rouleau; Mario Harvey; Chantal Guillemette
Journal:  J Biol Chem       Date:  2009-12-08       Impact factor: 5.157

2.  Enzymatic analysis of glucuronidation of synthetic cannabinoid 1-naphthyl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FDU-PB-22).

Authors:  Sabrina Jones; Azure L Yarbrough; Amal Shoeib; John M Bush; William E Fantegrossi; Paul L Prather; Anna Radominska-Pandya; Ryoichi Fujiwara
Journal:  Xenobiotica       Date:  2019-03-20       Impact factor: 1.908

3.  Enzyme Kinetics of Uridine Diphosphate Glucuronosyltransferases (UGTs).

Authors:  Jin Zhou; Upendra A Argikar; John O Miners
Journal:  Methods Mol Biol       Date:  2021

4.  Phenylalanine 93 of the human UGT1A10 plays a major role in the interactions of the enzyme with estrogens.

Authors:  Camilla Höglund; Nina Sneitz; Anna Radominska-Pandya; Liisa Laakonen; Moshe Finel
Journal:  Steroids       Date:  2011-08-09       Impact factor: 2.668

5.  Role of human UDP-glucuronosyltransferases in the biotransformation of the triazoloacridinone and imidazoacridinone antitumor agents C-1305 and C-1311: highly selective substrates for UGT1A10.

Authors:  Barbara Fedejko-Kap; Stacie M Bratton; Moshe Finel; Anna Radominska-Pandya; Zofia Mazerska
Journal:  Drug Metab Dispos       Date:  2012-06-01       Impact factor: 3.922

6.  Glucuronidation of the steroid enantiomers ent-17β-estradiol, ent-androsterone and ent-etiocholanolone by the human UDP-glucuronosyltransferases.

Authors:  Nina Sneitz; Kathiresan Krishnan; Douglas F Covey; Moshe Finel
Journal:  J Steroid Biochem Mol Biol       Date:  2011-08-27       Impact factor: 4.292

7.  Glucuronidation of psilocin and 4-hydroxyindole by the human UDP-glucuronosyltransferases.

Authors:  Nenad Manevski; Mika Kurkela; Camilla Höglund; Timo Mauriala; Michael H Court; Jari Yli-Kauhaluoma; Moshe Finel
Journal:  Drug Metab Dispos       Date:  2009-12-10       Impact factor: 3.922

8.  Human UDP-glucuronosyltransferase UGT2A2: cDNA construction, expression, and functional characterization in comparison with UGT2A1 and UGT2A3.

Authors:  Nina Sneitz; Michael H Court; Xiuling Zhang; Kaisa Laajanen; Karen K Yee; Pamela Dalton; Xinxin Ding; Moshe Finel
Journal:  Pharmacogenet Genomics       Date:  2009-12       Impact factor: 2.089

9.  Dopamine is a low-affinity and high-specificity substrate for the human UDP-glucuronosyltransferase 1A10.

Authors:  Katriina Itäaho; Michael H Court; Päivi Uutela; Risto Kostiainen; Anna Radominska-Pandya; Moshe Finel
Journal:  Drug Metab Dispos       Date:  2008-12-30       Impact factor: 3.922

10.  Evaluation of UGT protein interactions in human hepatocytes: effect of siRNA down regulation of UGT1A9 and UGT2B7 on propofol glucuronidation in human hepatocytes.

Authors:  Camille M Konopnicki; Leslie J Dickmann; Jeffrey M Tracy; Robert H Tukey; Larry C Wienkers; Robert S Foti
Journal:  Arch Biochem Biophys       Date:  2013-04-04       Impact factor: 4.013

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.